Statistici de bază
| LEI | 5493003LCY77N7FXK844 |
| CIK | 1484565 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Capnia, Inc. Warrants exp. 2019-02-01
SEC Filings (Chronological Order)
Această pagină oferă o listă completă, cronologică, a dosarelor SEC, cu excepția dosarelor de proprietate pe care le oferim în altă parte.
| May 28, 2026 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-36593 Soleno Therapeutics, Inc. (Exact name of registrant as spe |
|
| May 21, 2026 |
Soleno Therapeutics, Inc. 100 Marine Parkway, Suite 400 Redwood City, CA 94065 AW Soleno Therapeutics, Inc. 100 Marine Parkway, Suite 400 Redwood City, CA 94065 VIA EDGAR May 21, 2026 Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 RE: Soleno Therapeutics, Inc. Request for Withdrawal of Post-Effective Amendment No. 1 to Registration Statement on Form S-3 filed as form type “POSASR” File No. 333-275120 Ladies a |
|
| May 21, 2026 |
As filed with the Securities and Exchange Commission on May 21, 2026 POS AM As filed with the Securities and Exchange Commission on May 21, 2026 Registration No. |
|
| May 18, 2026 |
AMENDED AND RESTATED CERTIFICATE OF INCORPORATION SOLENO THERAPEUTICS, INC. EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF SOLENO THERAPEUTICS, INC. FIRST. The name of this corporation is Soleno Therapeutics, Inc. SECOND. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, Wilmington, County of New Castle, 19808, and the name of the registered agent of the corporation in the State of Delaware at such addres |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 POSASR As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
AMENDED AND RESTATED SOLENO THERAPEUTICS, INC. (A DELAWARE CORPORATION) EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF SOLENO THERAPEUTICS, INC. (A DELAWARE CORPORATION) ARTICLE I OFFICES Section 1. Registered Office. The registered office of the corporation in the State of Delaware is 251 Little Falls Drive, City of Wilmington, County of New Castle, 19808 or in such other location as the Board of Directors of the corporation (the “Board of Directors”) may from tim |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 18, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 2) SOLENO THERAPEUTICS, INC. (Name of Subject Company) SOLENO THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per Share (Title of Class o |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 POSASR As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 18, 2026 |
As filed with the Securities and Exchange Commission on May 18, 2026 S-8 POS As filed with the Securities and Exchange Commission on May 18, 2026 Registration No. |
|
| May 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| April 30, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-365 |
|
| April 28, 2026 |
SC 14D9/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 (Amendment No. 1) SOLENO THERAPEUTICS, INC. (Name of Subject Company) (Name of Person Filing Statement) Common Stock, par value $0.001 per Share (Title of Class of Securities) 834203309 (C |
|
| April 20, 2026 |
SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT EX-99.(e)(17) Exhibit (e)(17) SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of November 17, 2025, (the “Effective Date”) by and between Soleno Therapeutics, Inc. (the “Company”), and Kevin Norrett (“Executive”). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement between |
|
| April 20, 2026 |
SC 14D9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 20, 2026 |
SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT EX-99.(e)(16) Exhibit (e)(16) SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of November 3, 2025, (the “Effective Date”) by and between Soleno Therapeutics, Inc. (the “Company”), and Manher (AJ) Joshi, MD (“Executive”). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement |
|
| April 7, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 7, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2026 |
EX-99.3 Exhibit 99.3 SLNO Employee FAQ 1. What was announced? • Soleno Therapeutics has entered into a definitive agreement to be acquired by Neurocrine Biosciences, a leading biopharmaceutical company dedicated to serving patients with under-addressed neuropsychiatric, neurological, psychiatric, endocrine and immunological disorders. • Neurocrine recognizes the value of VYKAT™ XR (diazoxide choli |
|
| April 6, 2026 |
EX-99.2 Exhibit 99.2 SLNO Employee Letter FROM: Dr. Anish Bhatnagar TO: All Soleno Employees SUBJ: Soleno’s Next Chapter Dear Team, From day one, we have maintained an unwavering focus on our mission: to develop and commercialize therapeutics to treat rare genetic disorders. In the last year alone, we’ve made transformative strides toward our goal. Together, we secured FDA approval for VYKAT™ XR |
|
| April 6, 2026 |
SC14D9C UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) Solicitation/Recommendation Statement Under Section 14(d)(4) of the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC. (Name of Subject Company) SOLENO THERAPEUTICS, INC. (Name of Person Filing Statement) Common Stock, par value $0.001 per Share (Title of Class of Securities) 834203 |
|
| April 6, 2026 |
EX-99.1 Exhibit 99.1 Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio VYKATTM XR (diazoxide choline) is the First and Only FDA Approved Treatment for Hyperphagia in Prader-Willi Syndrome and Represents a Transformative Therapy Expands Neurocrine’s High-Growth Commercial Portfolio to Three First-in-Class Medicines Including INGREZZA® (valbenazine) an |
|
| April 6, 2026 |
EX-99.4 OUR NEXT CHAPTER: Soleno Therapeutics to be Acquired by Neurocrine Biosciences Employee Town Hall April 6, 2026 Exhibit 99.4 Forward-Looking Statements This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of each of Soleno and Neurocrine, including statements relating to the ability to complete and |
|
| April 6, 2026 |
SLNO Prescribers / Physicians Letter EX-99.6 Exhibit 99.6 SLNO Prescribers / Physicians Letter Subject: An Update on the Future of Soleno Therapeutics [Dear NAME / INSERT STANDARD GREETING], I am writing to share important news about the future of Soleno Therapeutics. We have agreed to be acquired by Neurocrine Biosciences, a leading biopharmaceutical company dedicated to serving patients with under-addressed neuropsychiatric, neurol |
|
| April 6, 2026 |
SLNO KOLs / Patient Advocacy Groups Letter EX-99.5 Exhibit 99.5 SLNO KOLs / Patient Advocacy Groups Letter Subject: An Update on the Future of Soleno Therapeutics Dear [NAME / INSERT CUSTOMARY GREETING], I am writing to share important news about the future of Soleno Therapeutics. We have agreed to be acquired by Neurocrine Biosciences, a leading biopharmaceutical company dedicated to serving patients with under-addressed neuropsychiatric, |
|
| April 6, 2026 |
SLNO Social Media Post - LinkedIn EX-99.1 Exhibit 99.1 SLNO Social Media Post - LinkedIn We are pleased to announce that Soleno Therapeutics has entered into a definitive agreement to be acquired by @Neurocrine Biosciences. This transaction reflects the strength of our science, our ability to commercialize and the depth of talent and dedication across our team. It also represents the next step in our efforts to bring VYKAT™ XR (di |
|
| April 6, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 5, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| April 6, 2026 |
EX-10.1 Exhibit 10.1 TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), is made and entered into as of April 5, 2026, by and among Neurocrine Biosciences Inc., a Delaware corporation (“Parent”), Sigma Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”), and the undersigned holders (each, a “Holder” and collectively, the “Ho |
|
| April 6, 2026 |
EX-2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER by and among NEUROCRINE BIOSCIENCES, INC., SIGMA MERGER SUB, INC. and SOLENO THERAPEUTICS, INC. Dated as of April 5, 2026 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS & INTERPRETATIONS 2 1.1 Certain Definitions 2 1.2 Certain Interpretations 18 ARTICLE II THE OFFER 20 2.1 The Offer 20 2.2 Company Actions 22 ARTICLE III THE MERGER 23 3.1 Merger of P |
|
| March 16, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 16, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 16, 2026 |
AMENDED AND RESTATED BYLAWS OF SOLENO THERAPEUTICS, INC. As amended on March 16, 2026 EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF SOLENO THERAPEUTICS, INC. As amended on March 16, 2026 Soleno Confidential TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES 2 2.5 NOTICE OF STOCKHOLDERS’ MEETIN |
|
| February 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| February 26, 2026 |
EX-10.1 Exhibit 10.1 Soleno Therapeutics, Inc. 100 Marine Parkway Suite 400 Redwood City, CA 94065 650-213-8444 Main www.soleno.life February 25, 2026 Jennifer Fulk [email protected] Dear Jennifer: I am pleased to offer you a position with Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), as Chief Financial Officer. This position requires onsite presence at our headquarter |
|
| February 26, 2026 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer REDWOOD CITY, Calif., February 26, 2026 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Jennifer Fulk as Chief Financial Offi |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| February 25, 2026 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics U.K. Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| February 25, 2026 |
As filed with the Securities and Exchange Commission on February 25, 2026 S-8 As filed with the Securities and Exchange Commission on February 25, 2026 Registration No. |
|
| February 25, 2026 |
Exhibit 10.19 FIRST AMENDMENT TO OFFICE LEASE THIS FIRST AMENDMENT TO OFFICE LEASE (the “Amendment”) is made and entered into as of November 25, 2025, by and between 1 Twin Property Owner LLC, a Delaware limited liability company (“Landlord”), and Soleno Therapeutics, Inc., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are parties to that certain Office Lease dated June 13, 20 |
|
| February 25, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 SOLENO THERAPEUTICS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock $0. |
|
| February 25, 2026 |
CAPNIA, INC. EMPLOYMENT AGREEMENT Exhibit 10.7 CAPNIA, INC. EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is entered into as of May 15, 2015, (the "Effective Date") by and between Capnia, Inc. (the "Company"), and Anish Bhatnagar ("Executive"). 1. Duties and Scope of Employment. (a) Positions and Duties. Executive's employment agreement with the Company will commence on May 15, 2015 (the "Start Date"). Executive |
|
| February 25, 2026 |
Exhibit 10.17 SOLENO THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As most recently amended on January 21, 2026) Soleno Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain, and reward Directors who are |
|
| February 25, 2026 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., February 25, 2026 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the fourth quarter and f |
|
| February 25, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| January 23, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 21, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| January 23, 2026 |
SOLENO THERAPEUTICS, INC. KEY EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN EX-10.1 Exhibit 10.1 SOLENO THERAPEUTICS, INC. KEY EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN 1. Introduction. This Soleno Therapeutics, Inc. Key Executive Change in Control and Severance Plan (as may be amended from time to time, this “Plan”) has been adopted by Soleno Therapeutics, Inc. (the “Company”), effective as of January 21, 2026 (the “Effective Date”), in order to provide specified se |
|
| January 12, 2026 |
Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Select Preliminary Fourth Quarter and Full-Year 2025 Results REDWOOD CITY, Calif., January 12, 2026 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced select preliminary financial and operating results for the fourth quarter and full-yea |
|
| January 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 12, 2026 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| November 12, 2025 |
FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT November 10, 2025 EX-10.2 Exhibit 10.2 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT November 10, 2025 THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this “Amendment”) is entered into as of the date first written above, by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, VA 22314 (“Oxford”), as collateral agent (in suc |
|
| November 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| November 12, 2025 |
Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement EX-99.1 Exhibit 99.1 Soleno Therapeutics Announces Entry Into $100 Million Accelerated Share Repurchase Agreement REDWOOD CITY, Calif., November 11, 2025 – Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that its Board of Directors has authorized a share repurchase and that it has ent |
|
| November 12, 2025 |
EX-10.1 Exhibit 10.1 Jefferies LLC 520 Madison Avenue New York, NY 10022 Tel: 212.284.2300 Jefferies.com Execution MASTER CONFIRMATION ACCELERATED SHARE REPURCHASE TRANSACTIONS Date: November 10, 2025 To: Soleno Therapeutics, Inc. 100 Marine Parkway, Suite 400 Redwood City, CA 94065 Attention: [ ] Telephone: [ ] Email: [ ] Re: Accelerated Share Repurchase Transactions Ladies and Gentleman: T |
|
| November 4, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR REDWOOD CITY, Calif., November 4, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today reported financial results for the third quarter ended September 30, 20 |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 4, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| November 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| October 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 13, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| October 14, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Appoints Biopharmaceutical Executive Mark W. Hahn to its Board of Directors Appointment adds three decades of financial and operational leadership to Soleno’s Board REDWOOD CITY, Calif., October 13, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today an |
|
| September 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| August 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 18, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 18, 2025 |
EX-99.1 Corporate Presentation August 2025 | Soleno Therapeutics Exhibit 99.1 | © 2025 Soleno Therapeutics Certain Notices and Disclaimers Forward-Looking Statements This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentio |
|
| August 6, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports Second Quarter 2025 Financial Results REDWOOD CITY, Calif., August 6, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financi |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 6, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| August 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| July 11, 2025 |
424B5 1 d23450d424b5.htm 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) 2,352,941 Shares Common Stock We are offering 2,352,941 shares of our common stock, par value $0.001 per share. Our common stock is listed on the Nasdaq Capital Market under the symbol “SLNO.” The last reported sale price of our c |
|
| July 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 11, 2025 |
EX-1.1 2 d52794dex11.htm EX-1.1 Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. Shares of Common Stock Underwriting Agreement July 10, 2025 Goldman Sachs & Co. LLC Guggenheim Securities, LLC As representatives (the “Representatives”) of the several Underwriters named in Schedule I hereto, c/o Goldman Sachs & Co. LLC 200 West Street New York, New York 10282 c/o Guggenheim Securities, LLC 33 |
|
| July 11, 2025 |
SOLENO THERAPEUTICS ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 SOLENO THERAPEUTICS ANNOUNCES PRICING OF $200 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it has priced its previously announced underwritten public offering of 2,352,941 |
|
| July 11, 2025 |
SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCK EX-99.1 Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PROPOSED $200 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today that it intends to offer and sell $200 million of shares of its common stock in |
|
| July 11, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 SOLENO THERAPEUTICS INC Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid 1 Equity Common Stock, par value $0. |
|
| July 10, 2025 |
EX-99.1 Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PRELIMINARY FINANCIAL AND OPERATIONAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) - Soleno Therapeutics, Inc. (Soleno) (Nasdaq:SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and o |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 10, 2025 |
SUBJECT TO COMPLETION, DATED JULY 10, 2025 Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| June 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 5, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 Soleno Therapeutics, Inc. |
|
| May 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 7, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2025 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Update on U.S. Launch of VYKAT(TM) XR and Reports First Quarter 2025 Financial Results REDWOOD CITY, Calif., May 7, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided an update on the U.S. launch of VYKATTM XR and reported financial r |
|
| April 22, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ De |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| April 22, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| April 18, 2025 |
Letter from Marcum LLP dated April 18, 2025 Exhibit 16.1 April 18, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read the statements made by Soleno Therapeutics, Inc. under Item 4.01 of its Form 8-K dated April 18, 2025. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other statements of Soleno Therapeutics, Inc. co |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 26, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| March 26, 2025 |
Exhibit 99.1 Soleno Therapeutics Announces U.S. FDA Approval of VYKATTM XR to Treat Hyperphagia in Prader-Willi Syndrome First approved therapy to address hyperphagia in individuals with Prader-Willi syndrome Management to host conference call and webcast today, March 26th, at 5:30pm ET REDWOOD CITY, Calif., March 26, 2025 – Soleno Therapeutics, Inc. (NASDAQ: SLNO), a biopharmaceutical company dev |
|
| February 28, 2025 |
Exhibit 19.1 SOLENO THERAPEUTICS, INC. INSIDER TRADING POLICY and Guidelines with Respect to Certain Transactions in Securities (As amended on November 9, 2024) TABLE OF CONTENTS Page INTRODUCTION 1 Legal prohibitions on insider trading 1 Detection and prosecution of insider trading 1 Penalties for violation of insider trading laws and this Policy 1 Compliance Officer 2 Reporting violations 2 Pers |
|
| February 28, 2025 |
Exhibit 10.16 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreeme |
|
| February 28, 2025 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.17 SOLENO THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (As most recently amended and restated on February 25, 2025) Soleno Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain, and reward Dir |
|
| February 28, 2025 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| February 28, 2025 |
Employment Agreement by and between the Company and Meredith Manning, dated January 23, 2024 Exhibit 10.12 SOLENO THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into effective as of January 23, 2024, (the “Effective Date”) by and between Soleno Therapeutics, Inc. (the “Company”), and Meredith Manning (“Executive”). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement between the Executive |
|
| February 28, 2025 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics U.K. Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| February 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| February 28, 2025 |
As filed with the Securities and Exchange Commission on February 28, 2025 As filed with the Securities and Exchange Commission on February 28, 2025 Registration No. |
|
| February 28, 2025 |
Employment Agreement by and between the Company and Patricia Hirano, dated January 1, 2019 Exhibit 10.10 SOLENO THERAPEUTICS, INC. (FKA CAPNIA, INC.) EMPLOYMENT AGREEMENT This Employment Agreement (the "Agreement") is entered into effective as of January 1, 2019, (the "Effective Date") by and between Soleno Therapeutics, Inc. (FKA Capnia, Inc.) (the "Company"), and Patricia C. Hirano ("Executive"). 1. Duties and Scope of Employment. (a) Positions and Duties. This employment agreement be |
|
| February 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 27, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| February 27, 2025 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2024 Financial Results REDWOOD CITY, Calif., February 27, 2025 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourth quarter a |
|
| February 5, 2025 |
EX-99 3 ITEM7.txt EXHIBIT 99: ITEM 7 BlackRock Advisors, LLC Aperio Group, LLC BlackRock Investment Management (UK) Limited BlackRock Asset Management Canada Limited BlackRock Investment Management (Australia) Limited BlackRock Fund Advisors BlackRock Asset Management Ireland Limited BlackRock Institutional Trust Company, National Association BlackRock Financial Management, Inc. BlackRock Fund Man |
|
| February 5, 2025 |
EX-24 2 PowerOfAttorney.txt EXHIBIT 24: POWER OF ATTORNEY POWER OF ATTORNEY The undersigned, BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, Jam |
|
| January 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 21, 2025 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| December 17, 2024 |
Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| December 17, 2024 |
Exhibit 99.1 Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC Up to $200 million financing, includes $50 million upfront REDWOOD CITY, Calif., December 17, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced it has entered into a loan |
|
| November 26, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces FDA Extension of Review Period for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome PDUFA target action date extended by three months to March 27, 2025 REDWOOD CITY, Calif., November 26, 2024 – Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the tre |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 26, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commis |
|
| November 19, 2024 |
SLNO / Soleno Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d790258dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| November 14, 2024 |
SC 13G 1 p24-3169sc13g.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the a |
|
| November 14, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-1 2 p24-3169exhibit1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing addition |
|
| November 14, 2024 |
SLNO / Soleno Therapeutics, Inc. / JANUS HENDERSON GROUP PLC - JANUS AMENDMENT Passive Investment SC 13G/A 1 Soleno093024.txt JANUS AMENDMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 3* Name of Issuer: SOLENO THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 834203309 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designat |
|
| November 14, 2024 |
SLNO / Soleno Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d868392dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| November 12, 2024 |
SLNO / Soleno Therapeutics, Inc. / Adage Capital Management, L.P. Passive Investment SC 13G/A 1 p24-3040sc13ga.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)*, ** Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropr |
|
| November 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| November 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| November 6, 2024 |
Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results REDWOOD CITY, Calif., November 6, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the third quarter end |
|
| October 24, 2024 |
SLNO / Soleno Therapeutics, Inc. / BlackRock, Inc. Passive Investment SC 13G 1 us8342033094102424.txt us8342033094102424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) SOLENO THERAPEUTICS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 834203309 - (CUSIP Number) September 30, 2024 - (Date of Event Which Requires Filing of this Statement) Check the appropriate |
|
| October 21, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A 1 d890003dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 |
|
| October 15, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 11)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 |
|
| October 10, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 10)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 2* Name of Issuer: SOLENO THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 834203309 Date of Event Which Requires Filing of this Statement: 9/30/2024 Check the appropriate box to designate the rule pursuant to which this Schedule i |
|
| September 10, 2024 |
SLNO / Soleno Therapeutics, Inc. / Carlyle Group Inc. Activist Investment SC 13D/A 1 formsc13da.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washingt |
|
| September 5, 2024 |
SC 13G 1 ea0213665-13gvivosoleno.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) August 27, 2024 (Date of Event Which Requires Filing of this Stat |
|
| September 5, 2024 |
EX-99.1 2 ea021366501ex99-1soleno.htm JOINT FILING STATEMENT Exhibit 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint fili |
|
| August 15, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces Updates to its Board of Directors Ernest Mario, Ph.D. steps down as Chair for health reasons; Matthew Pauls, J.D., M.B.A. assumes role of Lead Independent Director Dawn Carter Bir, seasoned biotech executive with significant commercial and strategic expertise, joins the Board of Directors REDWOOD CITY, Calif., August 15, 2024 – Soleno Therapeutics, Inc. ( |
|
| August 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 9, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 7, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| August 7, 2024 |
Lease agreement between the Company and 1 Twin Property Owner, LLC dated June 13, 2024 Exhibit 10.1 SHORES CENTER OFFICE LEASE This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between 1 Twin Property Owner LLC, a Delaware limited liability company ("Landlord") and Soleno Therapeutics, Inc., a Delaware corporation ("Tenant"). SUMMARY OF BASIC LEASE INFORMATION TERMS OF LEASE D |
|
| August 7, 2024 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| August 7, 2024 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results REDWOOD CITY, Calif., August 7, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the second qua |
|
| August 7, 2024 |
As filed with the Securities and Exchange Commission on August 7, 2024 As filed with the Securities and Exchange Commission on August 7, 2024 Registration No. |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| July 19, 2024 |
Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM July 19, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Agent”), shares of the Company’s common |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| July 19, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Soleno Therapeutics, Inc. |
|
| July 19, 2024 |
Up to $150,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) Up to $150,000,000 Common Stock We have entered into an Open Market Sale AgreementSM, or the sales agreement, with Jefferies LLC, or Jefferies, relating to shares of our common stock offered by this prospectus supplement and the accompanying prospectus. In acco |
|
| July 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 19, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 28, 2024 |
Exhibit 99.1 Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome REDWOOD CITY, Calif., June 28, 2024 – Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today ann |
|
| June 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 28, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 13, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2024 |
Amended and Restated 2014 Equity Incentive Plan and forms of agreement thereunder Exhibit 10.1 AMENDED AND RESTATED SOLENO THERAPEUTICS, INC. 2014 EQUITY INCENTIVE PLAN (Effective as of June 6, 2024) 1. Purposes of the Plan. The purposes of this Plan are: • to attract and retain the best available personnel for positions of substantial responsibility, • to provide additional incentive to Employees, Directors and Consultants, and • to promote the success of the Company’s busines |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 10, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 9, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 10, 2024 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results REDWOOD CITY, Calif., May 9, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the first quarter ended Ma |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 2, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 7, 2024 |
SOLENO THERAPEUTICS ANNOUNCES PRICING OF APPROXIMATELY $138 MILLION PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 SOLENO THERAPEUTICS ANNOUNCES PRICING OF APPROXIMATELY $138 MILLION PUBLIC OFFERING OF COMMON STOCK REDWOOD CITY, Calif., May 2, 2024 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq: SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today the pricing of the underwritten public |
|
| May 7, 2024 |
Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT May 2, 2024 PIPER SANDLER & CO. GUGGENHEIM SECURITIES, LLC As Representatives of the several Underwriters named in Schedule I attached hereto c/o Piper Sandler & Co. 800 Nicollet Mall, Suite 800 Minneapolis, Minnesota 55402 c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New |
|
| May 6, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 PROSPECTUS SUPPLEMENT (To Prospectus dated January 2, 2024) 3,000,000 Shares of Common Stock We are offering 3,000,0000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “SLNO.” On May 1, 2024, the last reported sale price of shares of our co |
|
| May 2, 2024 |
Subject to completion, dated May 2, 2024 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-276344 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanyi |
|
| May 1, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Kevin Dai Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address and Telephone Number o |
|
| April 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| April 29, 2024 |
Exhibit 99.1 Soleno Therapeutics Receives Breakthrough Therapy Designation from U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome (PWS) First Ever Breakthrough Designation for a Drug Being Developed for PWS Designation is Based on Data from the Phase 3 Program for DCCR Planned Submission of a New Drug Application (NDA) for DCCR Remains on Track for Mid-2024 RE |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 17, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| April 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE SECURITIES EXCHANGE ACT OF 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): March 6, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| March 7, 2024 |
Exhibit 97.1 SOLENO THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY As adopted October 18, 2023 Soleno Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s pay-f |
|
| March 7, 2024 |
Exhibit 10.58 LICENSE AGREEMENT FOR SPACE AND SERVICES THIS LICENSE AGREEMENT FOR SPACE AND SERVICES (known as the “Agreement” or the “License”) is made and entered into as of the 8th day of February , 2024, by and among HUDSON TOWERS AT SHORE CENTER, LLC, a Delaware limited liability company, as licensor (“Licensor”) and SOLENO THERAPEUTICS, INC., a Delaware corporation, as licensee (“Licensee”). |
|
| March 7, 2024 |
Subsidiaries of Soleno Therapeutics, Inc. Exhibit 21.1 Subsidiaries of Soleno Therapeutics, Inc. Subsidiary Jurisdiction Soleno Therapeutics U.K. Ltd. United Kingdom Soleno Therapeutics Europe Ltd. Ireland Essentialis, Inc. Delaware |
|
| March 7, 2024 |
Outside Director Compensation Policy Exhibit 10.59 SOLENO THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (Adopted on March 5, 2024) Soleno Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to its members of the Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain, and reward Directors who are not employees of th |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended: December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No.: 001-36593 Soleno Therapeuti |
|
| March 7, 2024 |
Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2023 Financial Results REDWOOD CITY, Calif., March 6, 2024 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update, and reported financial results for the fourt |
|
| February 14, 2024 |
US8342033094 / SOLENO THERAPEUTICS INC / COMMODORE CAPITAL LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2024 |
SLNO / Soleno Therapeutics, Inc. / Nantahala Capital Management, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* SOLENO THERAPEUTICS, INC (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 834203200 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| February 13, 2024 |
SC 13G/A 1 solenojhbif123123.txt JHG PLC & JHBIF >5% UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 1* Name of Issuer: SOLENO THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 834203309 Date of Event Which Requires Filing of this Statement: 12/31/2023 Check the appropriate box t |
|
| February 7, 2024 |
SC 13G/A 1 p24-0474sc13ga.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Stateme |
|
| January 31, 2024 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| January 31, 2024 |
As filed with the Securities and Exchange Commission on January 31, 2024 As filed with the Securities and Exchange Commission on January 31, 2024 Registration No. |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 24, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commiss |
|
| January 30, 2024 |
2020 Inducement Equity Incentive Plan, as amended on January 24, 2024 Exhibit 10.1 SOLENO THERAPEUTICS, INC. 2020 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purposes of the Plan. The purposes of this Plan are to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subsidiary of the Company. The Plan permits the grant of Nonsta |
|
| January 17, 2024 |
As filed with the Securities and Exchange Commission on January 17, 2024 S-8 As filed with the Securities and Exchange Commission on January 17, 2024 Registration No. |
|
| January 17, 2024 |
Calculation of Filing Fees Table EX-FILING FEES Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| January 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 4, 2024 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| January 2, 2024 |
EX-4.3 Exhibit 4.3 SOLENO THERAPEUTICS, INC. INDENTURE Dated as of, 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 5 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 6 ARTICLE II THE SECURITIES 6 Section 2.1 Issuable in Series 6 Section 2.2 Establish |
|
| January 2, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Soleno Therapeutics, Inc. |
|
| January 2, 2024 |
As filed with the Securities and Exchange Commission on January 2, 2024 S-3ASR Table of Contents As filed with the Securities and Exchange Commission on January 2, 2024 Registration No. |
|
| November 8, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| October 27, 2023 |
October 27, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Soleno Therapeutics, Inc. Registration Statement on Form S-3 File No. 333- 275120 Acceleration Request Requested Date: October 31, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under th |
|
| October 27, 2023 |
United States securities and exchange commission logo October 27, 2023 James Mackaness Chief Financial Officer Soleno Therapeutics, Inc. |
|
| October 23, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| October 20, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) SOLENO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amo\unt of Registration Fee Fees to be Paid Equity Common |
|
| October 20, 2023 |
As filed with the Securities and Exchange Commission on October 20, 2023 Table of Contents As filed with the Securities and Exchange Commission on October 20, 2023 Registration No. |
|
| October 16, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| October 12, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / COMMODORE CAPITAL LP Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate b |
|
| October 12, 2023 |
SC 13G 1 p23-2583sc13g.htm SOLENO THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) October 2, 2023 (Date of Event Which Requires Filing of This Statement) Chec |
|
| October 11, 2023 |
SC 13D/A 1 ea186624-13da1vivosoleno.htm AMENDMENT NO. 1 TO SCHEDULE 13D SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Hongbo Lu Vivo Capital LLC 192 Lytton Avenue Palo Alto, |
|
| October 10, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / Fairmount Funds Management LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Securities) 834203309 (CUSIP Number) September 28, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pu |
|
| October 6, 2023 |
SC 13G 1 soleno092623.txt JHG PLC OWNS 10.1% OF SOLENO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment No.: 0* Name of Issuer: SOLENO THERAPEUTICS, INC. Title of Class of Securities: Common Stock CUSIP Number: 834203309 Date of Event Which Requires Filing of this Statement: 9/26/2023 Check the appropriate box |
|
| October 5, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* SOLENO THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) September 26, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| October 3, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| October 3, 2023 |
EX-99.4 2 d533581dex994.htm EX-99.4 Exhibit 99.4 POWER OF ATTORNEY The undersigned understands that, from time to time, the Carlyle Companies (defined below) are required to prepare, execute, and file certain federal and state securities laws filings. Know all by these presents, that the undersigned hereby constitutes and appoints each of Jeffrey Ferguson, Jeremy Anderson, Chintan Bhatt, Anne Fred |
|
| September 29, 2023 |
Exhibit 1.1 Execution Version SOLENO THERAPEUTICS, INC. 3,000,000 Shares of Common Stock UNDERWRITING AGREEMENT September 28, 2023 Guggenheim Securities, LLC As Representative of the several Underwriters named in Schedule I attached hereto c/o Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Ladies and Gentlemen: Soleno Therapeutics, Inc., a corporation organized and existing |
|
| September 29, 2023 |
Exhibit 1.2 Execution Version 1,825,000 Shares of Common Stock Pre-Funded Warrants to Purchase 1,175,000 Shares of Common Stock Soleno Therapeutics, Inc. PLACEMENT AGENCY AGREEMENT September 28, 2023 Guggenheim Securities, LLC 330 Madison Avenue New York, New York 10017 Cantor Fitzgerald & Co. 110 East 59th Street, 6th Floor New York, New York 10022 Oppenheimer & Co. Inc. 85 Broad Street New York, |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 28, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| September 29, 2023 |
3,000,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 PROSPECTUS SUPPLEMENT (To Prospectus dated February 9, 2021) 3,000,000 Shares of Common Stock We are offering 3,000,000 shares of our common stock, par value $0.001 per share. Our common stock is listed on The Nasdaq Capital Market under the symbol “SLNO.” On September 27, 2023, the last reported sale price of shares of |
|
| September 29, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d498788dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| September 29, 2023 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Soleno Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on Exhibit A hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”). RECITALS WHEREAS, on the terms and subject to t |
|
| September 29, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Pricing of Approximately $120 Million Underwritten Public Offering of Common Stock and Concurrent Private Placement of Common Stock and/or Pre-Funded Warrants September 28, 2023 REDWOOD CITY, Calif., September 28, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (Nasdaq:SLNO), (“Soleno” or the “Company”), a clinical-stage biopharmaceutical company develo |
|
| September 29, 2023 |
Exhibit 10.2 NEITHER THIS WARRANT, NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THIS WARRANT (COLLECTIVELY, THE “SECURITIES”), HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR UNDER ANY STATE SECURITIES OR BLUE SKY LAWS. THE SECURITIES ARE SUBJECT TO RESTRICTIONS ON TRANSFERABILITY AND RESALE AND MAY NOT BE OFFERED, SOLD, PLEDGED, HYPOTHECATED OR OTHERWI |
|
| September 28, 2023 |
Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated September 28, 2023 Relating to Preliminary Prospectus Supplement Dated September 27, 2023 Registration Statement Nos. |
|
| September 28, 2023 |
FWP Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Dated September 28, 2023 Relating to Preliminary Prospectus Supplement Dated September 27, 2023 Registration Statement Nos. |
|
| September 27, 2023 |
SUBJECT TO COMPLETION, DATED SEPTEMBER 27, 2023 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are part of an effective registration statement filed with the Securities and Exchange Commission. This preliminary prospectus supplement and the acco |
|
| September 27, 2023 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) SOLENO THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to be Paid Equity Common |
|
| September 27, 2023 |
As filed with the Securities and Exchange Commission on September 27, 2023 As filed with the Securities and Exchange Commission on September 27, 2023 Registration No. |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| September 26, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Positive Statistically Significant Top-line Results from Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Study Met Primary Endpoint; Highly Statistically Significant Difference in Change from Baseline in HQ-CT Total Score for DCCR Compared to Placebo (p=0.0022) Soleno Intends to Submit a New Drug Application for DCCR in PWS Mi |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 26, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commi |
|
| August 30, 2023 |
SLNO / Soleno Therapeutics Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 2 Under the Securities Exchange Act of 1934 SOLENO THERAPEUTICS, INC (Name of Issuer) Common Shares (Title of Class of Securities) 834203200 (CUSIP Number) June 6, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch |
|
| August 18, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 6)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| August 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 15, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissi |
|
| August 16, 2023 |
Exhibit 99.1 Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors REDWOOD CITY, Calif., August 16, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board |
|
| August 15, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| August 8, 2023 |
FIRST AMENDMENT THIS FIRST AMENDMENT (this “Amendment”) is made and entered into as of April 24 , 2023, by and between HUDSON TOWERS AT SHORE CENTER, LLC, a Delaware limited liability company (“Landlord”), and SOLENO THERAPEUTICS, INC. |
|
| August 8, 2023 |
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2023 Financial Results REDWOOD CITY, Calif., August 8, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the second quarter ende |
|
| August 8, 2023 |
Calculation of Filing Fees Table Exhibit 107 CALCULATION OF REGISTRATION FEE TABLES Form S-8 (Form Type) Soleno Therapeutics, Inc. |
|
| August 8, 2023 |
As filed with the Securities and Exchange Commission on August 8, 2023 As filed with the Securities and Exchange Commission on August 8, 2023 Registration No. |
|
| August 8, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 8, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commissio |
|
| July 31, 2023 |
July 31, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Abby Adams Re: Soleno Therapeutics, Inc. Registration Statement on Form S-1 File No. 333- 273373 Acceleration Request Requested Date: August 2, 2023 Requested Time: 4:00 P.M. Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under the Securities |
|
| July 28, 2023 |
United States securities and exchange commission logo July 28, 2023 James Mackaness Chief Financial Officer Soleno Therapeutics, Inc. |
|
| July 28, 2023 |
As filed with the Securities and Exchange Commission on July 28, 2023 S-1/A Table of Contents As filed with the Securities and Exchange Commission on July 28, 2023 Registration No. |
|
| July 21, 2023 |
Power of Attorney (included on the signature page to this Registration Statement) S-1 Table of Contents As filed with the Securities and Exchange Commission on July 21, 2023 Registration No. |
|
| July 21, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Soleno Therapeutics, Inc. |
|
| July 10, 2023 |
EX-99.1 Exhibit 99.1 Corporate Presentation July 2023 | Soleno Therapeutics Certain Notices and Disclaimers Forward-Looking Statements This presentation contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements appear in a number of places throughout this presentation and include statements regarding our intentions, beliefs, projections, outlo |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 10, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| June 6, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| June 2, 2023 |
Up to $8,878,028 of Shares Common Stock 424B5 Filed Pursuant to Rule 424(b)(5) Registration No. 333-252108 AMENDMENT NO. 2 DATED JUNE 2, 2023 to Prospectus Supplement dated July 16, 2021 (To Prospectus dated February 9, 2021) Up to $8,878,028 of Shares Common Stock This Amendment No. 2 to Prospectus Supplement (this “Amendment”) amends our prospectus supplement dated July 16, 2021 (the “Prospectus Supplement”). This Amendment should be |
|
| June 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203309 (CUSIP Number) Frank Kung Vivo Capital LLC 192 Lytton Avenue Palo Alto, CA 94301 Telephone: (650) 688-0818 (Name, Address and Telephone Number o |
|
| June 1, 2023 |
Joint Filing Agreement (filed herewith). Exhibit 99.1 JOINT FILING AGREEMENT The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D may be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned acknowledge that each shall be r |
|
| May 30, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address |
|
| May 26, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / SCHULER JACK W Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 25, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission |
|
| May 25, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D/A Activist Investment SC 13D/A 1 d444551dsc13da.htm SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 |
|
| May 18, 2023 |
EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The persons below hereby agree that the Schedule 13D to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13D, shall be filed jointly on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Dated: May 18, 2023 PERCEPT |
|
| May 18, 2023 |
US8342033094 / SOLENO THERAPEUTICS INC / PERCEPTIVE ADVISORS LLC - SC 13D Activist Investment SC 13D SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment )* Soleno Thereputics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203309 (CUSIP Number) Alexander Rakitin Perceptive Advisors LLC 51 Astor Place, 10th Floor New York, NY 10003 (646) 205-5340 (Name, Address and Telep |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 834203200 (CUSIP Number) May 8, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| May 15, 2023 |
EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each shall be |
|
| May 10, 2023 |
SLNO / Soleno Therapeutics Inc / Carlyle Group Inc. - SC 13D/A Activist Investment SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Soleno Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 834203200 (CUSIP Number) Jeffrey Ferguson The Carlyle Group 1001 Pennsylvania Avenue, NW Suite 220 South Washington, D.C. 20004 (202) 729-5626 ( |
|
| May 9, 2023 |
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results EX-99.1 Exhibit 99.1 Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results REDWOOD CITY, Calif., May 9, 2023 – Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today provided a corporate update and reported financial results for the first quarter e |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 8, 2023 SOLENO THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36593 77-0523891 (State or other jurisdiction of incorporation) (Commission F |
|
| May 9, 2023 |
2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36593 SOLENO THERAPEUTICS, INC. |
|
| May 3, 2023 |
EX-99.1 Exhibit 99.1 Soleno Therapeutics Completes Enrollment in Randomized Withdrawal Period of Study C602 of DCCR for Prader-Willi Syndrome Top-line data expected in Q3 2023 and has the potential to support an NDA submission for DCCR in Prader Willi Syndrome Enrollment completion satisfies closing condition on December 2022 Securities Purchase Agreement and triggers $10 million capital infusion |
